Ignite Creation Date:
2024-05-06 @ 7:24 AM
Last Modification Date:
2024-10-26 @ 11:47 AM
Study NCT ID:
NCT02521038
Status:
UNKNOWN
Last Update Posted:
2017-10-09
First Post:
2015-08-04
Brief Title:
Use of Ticagrelor in Korean ACS Patients The BRILIANT KOREA Registry
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
The Use of BRILInta to Optimize ANTiplatelet Therapy BRILIANT Registry The BRILIANT KOREA Registry
Status:
UNKNOWN
Status Verified Date:
2017-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with acute coronary syndrome ACS require platelet inhibition after treatment P2Y12 receptor blockage is a well-known proved method of urgent and effective blockade of the platelet activation and is applied to the current practice protocol Ticagrelor is a well-performing P2Y12 receptor blocking agent which is used in these patients In the same matter it is essential to prescribe the exact dosage to optimize efficacy within the safety limits However current studies are based on Western countries whereas there has been no Ticagrelor patient registry in East-Asia Thus it is reasonable to study the use of Ticagrelor in a large registry of Korean ACS patients
The BK registry is a Prospective Open-label Multi-center Real world Registry with prospective registration of patients receiving the medication Ticagrelor All subjects are to be followed up for 18 months after diagnosis and treatment for ACS
The purpose of this study is to observe and register clinical data including Major Adverse Cardiovascular Endpoints and any total bleeding occurrence in Korean ACS patients treated with Ticagrelor during 18 month follow-up Also the purpose includes to determine compliance of Ticagrelor during post-approval commercial use and to determine prescription pattern of Ticagrelor during post-approval commercial use
The BK registry is a Prospective Open-label Multi-center Real world Registry with prospective registration of patients receiving the medication Ticagrelor All subjects are to be followed up for 18 months after diagnosis and treatment for ACS
The purpose of this study is to observe and register clinical data including Major Adverse Cardiovascular Endpoints and any total bleeding occurrence in Korean ACS patients treated with Ticagrelor during 18 month follow-up Also the purpose includes to determine compliance of Ticagrelor during post-approval commercial use and to determine prescription pattern of Ticagrelor during post-approval commercial use
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None